<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972021000200096</article-id>
<article-id pub-id-type="doi">10.26445/06.02.14</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Amiloidosis muscular. A propósito de un caso clínico.]]></article-title>
<article-title xml:lang="en"><![CDATA[Muscle amyloidosis. About a clinical case.]]></article-title>
<article-title xml:lang="pt"><![CDATA[Amiloidose muscular. Sobre um caso clínico.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Roldan]]></surname>
<given-names><![CDATA[Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fagúndez]]></surname>
<given-names><![CDATA[Yohana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sarachaga]]></surname>
<given-names><![CDATA[María Eugenia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bradvica]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central de las Fuerzas Armadas Departamento de Medicina Departamento de Hematología]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>07</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>07</month>
<year>2021</year>
</pub-date>
<volume>6</volume>
<numero>2</numero>
<fpage>96</fpage>
<lpage>103</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972021000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972021000200096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972021000200096&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La amiloidosis engloba distintas enfermedades caracterizadas por el depósito extracelular de una proteína anómala e insoluble (amiloide) en los diferentes tejidos, causando su disfunción progresiva. La presentación clínica suele ser heterogénea, lo que determina el diagnóstico tardío. Para alcanzarlo se requiere de biopsia del tejido afectado, la demostración del depósito amiloide y la tipificación de la proteína que lo constituye. La detección precoz permite optimizar el tratamiento, condicionando esto el pronóstico. La miopatía amiloide asociada a una discrasia de células plasmáticas es una causa infrecuente de hipertrofia muscular; por lo que en el siguiente artículo se busca presentar un caso clínico de la misma con posterior revisión de la literatura.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Amyloidosis encompasses various diseases characterized by the extracellular deposition of an abnormal and insoluble (amyloid) protein among the different tissues, causing its progressive dysfunction. The clinical presentation is usually heterogeneous, which determines the delays in diagnosis. To achieve this, a biopsy of the affected tissue, the demonstration of amyloid deposit and the typing of the protein that constitutes it are required. Early detection allows optimizing the treatment, conditioning the prognosis. Amyloid myopathy associated with plasma cell dyscrasia is an infrequent cause of muscle hypertrophy, for which reason the following article seeks to present a clinical case of it with a subsequent review of the literature.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: A amiloidose engloba diferentes doenças caracterizadas pela deposição extracelular de uma proteína anormal e insolúvel (amiloide) em diferentes tecidos, causando sua disfunção progressiva. A apresentação clínica costuma ser heterogênea, o que determina o diagnóstico tardio. Para tanto, é necessária a biópsia do tecido afetado, a demonstração do depósito amilóide e a tipagem da proteína que o constitui. A detecção precoce permite otimizar o tratamento, condicionando o prognóstico. A miopatia amilóide associada à discrasia das células plasmáticas é uma causa rara de hipertrofia muscular; Portanto, o seguinte artigo busca apresentar um caso clínico desta com posterior revisão da literatura.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[amiloidosis]]></kwd>
<kwd lng="es"><![CDATA[miopatía amiloide]]></kwd>
<kwd lng="es"><![CDATA[hipertrofia muscular]]></kwd>
<kwd lng="en"><![CDATA[amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[amyloid myopathy]]></kwd>
<kwd lng="en"><![CDATA[muscle hypertrophy]]></kwd>
<kwd lng="pt"><![CDATA[amiloidose]]></kwd>
<kwd lng="pt"><![CDATA[miopatia amilóide]]></kwd>
<kwd lng="pt"><![CDATA[hipertrofia muscular]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiloidosis ¿Cuándo sospecharla y cómo diagnosticarla?]]></article-title>
<source><![CDATA[Rev Tendencias en medicina]]></source>
<year>2018</year>
<volume>52</volume>
<page-range>156-61</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comenzo]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How I treat amyloidosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>114</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>3147-57</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiloidosis primaria (Internet)]]></article-title>
<source><![CDATA[Rev Opción médica]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Specht]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The neuromuscular manifestations of amyloidosis]]></article-title>
<source><![CDATA[J Clin Neuromuscul Dis]]></source>
<year>2010</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-57</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Pavía]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tomé-Esteban]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiloidosis También una enfermedad del corazón]]></article-title>
<source><![CDATA[Rev esp cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>797-808</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Larraburu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Manejo actual de las discrasias plasmocitarias (Internet)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Janssen]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kornfeld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amyloid myopathy characteristic features of a still underdiagnosed disease]]></article-title>
<source><![CDATA[Muscle and Nerve]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>266-72</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Seldin]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Gertz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amyloidosis pathogenesis and new therapeutic options]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1924-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venner]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Foard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rannigan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Pinney]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>4387-90</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is new in diagnosis and management of light chain amyloidosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2016</year>
<volume>128</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>159-68</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manoli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Rushing]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tsokos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic myopathy due to immunoglobulin light chain amyloidosis]]></article-title>
<source><![CDATA[Mol Genet Metab]]></source>
<year>2013</year>
<volume>108</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>249-54</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liewluck]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Milone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of isolated amyloid myopathy]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2017</year>
<volume>24</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1437-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Accardi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Capozzi]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Capello]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Verga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Rare Case of Systemic AL Amyloidosis with Muscle Involvement A Misleading Diagnosis]]></article-title>
<source><![CDATA[Case Rep Hematol]]></source>
<year>2018</year>
<volume>2018</volume>
<page-range>9840405</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muchtar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Derudas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mauermann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liewluck]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic immunoglobulin light chain amyloidosis-associated myopathy presentation, diagnostic pitfalls, and outcome]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2016</year>
<volume>91</volume>
<page-range>1354-61</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
